SciNeuro Pharmaceuticals, a Chinese manufacturer of drugs for central nervous system (CNS) diseases, said that it has garnered $100 million in a Series A round funding jointly led by Lilly Asia Ventures (LAV) and Arch Venture Partners.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
